Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 9:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 2,449 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ABI-007(Abraxane) Clear all
Completed Phase 2 Interventional

Paclitaxel and Capecitabine in Treating Women With Metastatic Breast Cancer

NCT00005649
View directory record Official record
Conditions
Breast Cancer
Interventions
capecitabine, paclitaxel
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Oct 18, 2026, 9:43 AM EDT
Completed Phase 2 Interventional

S9712: Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III Non-small Cell Lung Cancer

NCT00003158
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, etoposide, paclitaxel, radiation therapy
Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2007
U.S. locations
86
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2012 · Synced Oct 18, 2026, 9:43 AM EDT
Active, not recruiting Phase 2 Interventional

Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)

NCT04443348
View directory record Official record
Conditions
Triple Negative Breast Cancer, Hormone Receptor Positive (HR+), HER2-negative Breast Cancer, Biopsy-proven, Positive Lymph Node(s)
Interventions
Radiation Therapy Boost, Pembrolizumab, Paclitaxel, Carboplatin, Cyclophosphamide, Doxorubicin, Capecitabine
Radiation · Drug
Lead sponsor
Laura M. Spring, MD
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
10
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 18, 2026, 9:43 AM EDT
Active, not recruiting Phase 2 Interventional

To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations

NCT06194448
View directory record Official record
Conditions
Lung Cancer
Interventions
Osimertinib, Cisplatin or Carboplatin; Pemetrexed or Paclitaxel, Radiation
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
La Jolla, California • Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 18, 2026, 9:43 AM EDT
Suspended Phase 1 Interventional

A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies

NCT01604863
View directory record Official record
Conditions
Cancer
Interventions
HGS1036 + Paclitaxel + Carboplatin, HGS1036 + Cisplatin + Etoposide, HGS1036 + Docetaxel
Drug
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Scottsdale, Arizona • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2012 · Synced Oct 18, 2026, 9:43 AM EDT
Completed Phase 2 Interventional Results available

A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors

NCT01515306
View directory record Official record
Conditions
Malignant Solid Tumor
Interventions
ramucirumab (IMC-1121B), paclitaxel
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
6
States / cities
Ann Arbor, Michigan • Detroit, Michigan • New Brunswick, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Oct 18, 2026, 9:43 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer

NCT01632306
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
LY2090314, FOLFOX, Gemcitabine, Nab-paclitaxel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Oct 18, 2026, 9:43 AM EDT
Completed Phase 2 Interventional Results available

Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer

NCT01818063
View directory record Official record
Conditions
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-negative Breast Cancer
Interventions
Paclitaxel, Carboplatin, Doxorubicin, Cyclophosphamide, Veliparib
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
Bethesda, Maryland • Philadelphia, Pennsylvania • Reading, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 18, 2026, 9:43 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).

NCT03164616
View directory record Official record
Conditions
Non Small Cell Lung Cancer NSCLC
Interventions
Durvalumab, Tremelimumab, Abraxane + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + carboplatin, Pemetrexed + cisplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
16
States / cities
Phoenix, Arizona • Bakersfield, California • Santa Monica, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 18, 2026, 9:43 AM EDT
Completed Phase 2 Interventional Results available

Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer

NCT02769832
View directory record Official record
Conditions
Small Cell Lung Cancer (SCLC)
Interventions
Nab-paclitaxel, Gemcitabine
Drug
Lead sponsor
Muhammad Furqan
Other
Eligibility
18 Years to 99 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 18, 2026, 9:43 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer

NCT02641639
View directory record Official record
Conditions
Platinum Resistant Ovarian Cancer
Interventions
Fosbretabulin tromethamine, Placebo
Drug
Lead sponsor
Mateon Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
36
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 18, 2026, 9:43 AM EDT
Terminated Phase 2 Interventional Results available

Induction Chemo-Nivo in Unresectable Stage III NSCLC

NCT06003075
View directory record Official record
Conditions
Lung Cancer, Nonsmall Cell, Lung Cancer Stage III
Interventions
Nivolumab and Chemotherapy, Nivolumab, Post Induction Surgery, Post Induction XRT
Combination Product · Drug · Procedure + 1 more
Lead sponsor
Ralph G Zinner
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 18, 2026, 9:43 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer

NCT01647828
View directory record Official record
Conditions
Stage IV Pancreatic Cancer
Interventions
OMP-59R5, Gemcitabine, Placebo, Nab-Paclitaxel
Drug
Lead sponsor
OncoMed Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
26
States / cities
Goodyear, Arizona • Bakersfield, California • Fullerton, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 18, 2026, 9:43 AM EDT
Completed Phase 2 Interventional

Bryostatin 1 Plus Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer or Stomach Cancer

NCT00005599
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
bryostatin 1, paclitaxel
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
2
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2013 · Synced Oct 18, 2026, 9:43 AM EDT
Completed Phase 1 Interventional

Calcium and Magnesium Infusion for the Prevention of Taxane Induced Neuropathy

NCT01682499
View directory record Official record
Conditions
Paclitaxel-induced Neuropathy
Interventions
calcium gluconate and magnesium sulfate
Drug
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
21 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Oct 18, 2026, 9:43 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca

NCT02957968
View directory record Official record
Conditions
Breast Adenocarcinoma, Estrogen Receptor- Negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Progesterone Receptor Positive Tumor, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Triple-negative Breast Carcinoma
Interventions
Doxorubicin, Cyclophosphamide, Paclitaxel, Carboplatin, Decitabine, Pembrolizumab
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
4
States / cities
Edgewood, Kentucky • Columbus, Ohio • Charlottesville, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 18, 2026, 9:43 AM EDT
Recruiting Phase 3 Interventional

Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Bowel

NCT05561127
View directory record Official record
Conditions
Bowel; Stricture
Interventions
GIE Medical ProTractX3 TTS DCB, Control
Combination Product · Other
Lead sponsor
GIE Medical
Industry
Eligibility
22 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
32
States / cities
Scottsdale, Arizona • Irvine, California • Lancaster, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 18, 2026, 9:43 AM EDT
Completed Phase 2 Interventional Results available

Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer

NCT00655850
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Paclitaxel, Gemcitabine, Avastin
Drug · Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Oct 18, 2026, 9:43 AM EDT
Recruiting Phase 3 Interventional

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

NCT05624996
View directory record Official record
Conditions
Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
Interventions
Carboplatin, Cisplatin, Computed Tomography, Durvalumab, Etoposide, Image Guided Radiation Therapy, Nab-paclitaxel, Osimertinib, Paclitaxel, Pemetrexed, Positron Emission Tomography, Questionnaire Administration, Stereotactic Body Radiation Therapy
Drug · Procedure · Biological + 2 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2036
U.S. locations
476
States / cities
Birmingham, Alabama • Daphne, Alabama • Fairhope, Alabama + 357 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 18, 2026, 9:43 AM EDT
Completed Phase 3 Interventional Results available

GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma

NCT01245062
View directory record Official record
Conditions
Melanoma
Interventions
GSK1120212, Chemotherapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
13
States / cities
Tucson, Arizona • Fort Myers, Florida • Athens, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 18, 2026, 9:43 AM EDT
Completed Phase 2 Interventional Results available

Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas

NCT01088815
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
Gemcitabine, nab-Paclitaxel, GDC-0449
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
3
States / cities
Scottsdale, Arizona • Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 26, 2019 · Synced Oct 18, 2026, 9:43 AM EDT
Completed Phase 2 Interventional Results available

Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer

NCT02440425
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Pembrolizumab, Paclitaxel
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
3
States / cities
Tampa, Florida • Durham, North Carolina • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 7, 2022 · Synced Oct 18, 2026, 9:43 AM EDT
Recruiting Phase 2 Interventional

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

NCT05061550
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Durvalumab, Oleclumab, Monalizumab, Dato-DXd, AZD0171, Carboplatin, Cisplatin, Pemetrexed/Cisplatin, Pemetrexed/Carboplatin, Carboplatin/Paclitaxel, Volrustomig, Rilvegostomig
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 95 Years
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
24
States / cities
Little Rock, Arkansas • Los Angeles, California • Oakland, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 18, 2026, 9:43 AM EDT
Terminated Phase 2 Interventional Results available

Weight-based Dosing for Dense Weekly Paclitaxel and Carboplatin in Overweight Patients w/ Body Surface Area (BSA) > 2.0

NCT02756013
View directory record Official record
Conditions
Gynecologic Malignancies
Interventions
Paclitaxel, Carboplatin
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Oct 18, 2026, 9:43 AM EDT